



10-20-04

JFW

PATENT
DOCKET NO. JHV-028.01

In re Application of:

Gallagher, M., et al.

Application No: 10/722,357

Filed: November 24, 2003

For: Target for Therapy of Cognitive
Impairment

Art Unit: 1641


Attorney Docket: JHV-028.01

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Number: EV 327704845 US, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on October 19, 2004.



Kristen M. Williams

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Because this application was filed after June 30, 2003, copies of the U.S. patents are not enclosed. However, a copy of the foreign patent documents and copies of the references are also being submitted.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:


- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

If the Examiner has any questions, or if a teleconference would advance the instant application toward allowance, the Examiner is urged to telephone the undersigned at 202-261-7356.

Date: October 19, 2004

Customer No.: 25181
Patent Group
Foley Hoag LLP
155 Seaport Boulevard
Boston, MA 02210
617-832-1000
617-832-7000 (FAX)

Respectfully Submitted,

A handwritten signature in dark ink, appearing to read "Gillian M. Fenton", is written over a horizontal line.

Gillian M. Fenton
Reg. No. 36,508
Attorney for Applicant

| | | |
|--|---|---|
| Form PTO-1449 | Docket Number (Optional) JHV-028.01 | Application Number 10/722,357 |
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i> | | |
| Applicant Gallagher, Michela et al. | | |
| Filing Date November 24, 2003 | | Group Art Unit 1641 |

U.S. PATENT DOCUMENTS

| EXAMINER DATE | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|------------------|-----------------|--------------|--------------------|---|----------|-------------------------------|
| | A1 | 6,489,319 B1 | December 3, 2002 | Neurotherapeutic Use of Carboxypeptidase Inhibitors | | February 14, 2001 |
| | A2 | 6,627,625 B1 | September 30, 2003 | Treatment of Behavioral Disorders with β -Lactam Compounds | | August 16, 2000 |
| | A3 | 6,683,075 B1 | January 27, 2004 | Cycloalkyl, Lactam, Lactone and Related Compounds, Pharmaceutical Compositions Comprising Same, and Methods for Inhibiting β -Amyloid Peptide Release And/Or Its Synthesis By Use | | January 6, 2003 |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | Translation | |
|--|-----------------|-------------------|-------------------|-------|----------|-------------|----|
| | | | | | | YES | NO |
| | B1 | WO 2004/076675 A2 | 10 September 2004 | PCT | C12P | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

| | | |
|--|--|--|
| | | |
| | | |
| | | |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.